Key result
The serotype O FMD mRNA vaccine provided complete protection (100% survival) for guinea pigs against a lethal challenge of 100 GPID50, with protection equivalent to the inactivated vaccine.
Why the study?
Traditional inactivated FMDV vaccines pose risks of virus dissemination and serotype matching challenges, attenuated vaccines are forbidden, and alternative vaccines offer inadequate immune protection.
A novel serotype O FMD mRNA vaccine induces robust cellular and humoral immunity and provides complete protection against lethal viral challenge in guinea pigs, presenting a promising alternative to traditional inactivated vaccines.
Answers are grounded in this paper and cite their sources.
Preliminary guinea pig protection data supports mRNA FMDV vaccine development; leaves open translation to livestock efficacy and field use.
Foot-and-mouth disease virus (FMDV) is one of the most significant animal pathogens worldwide, severely impacting the health and productivity of pigs, cattle, sheep, and other ungulates. Although the traditional vaccines have played a crucial role in epidemic control, inactivated vaccines face persistent challenges concerning the potential for virus dissemination and pressures from serotype and subtype matching. However, the manufacture of attenuated vaccines is forbidden, and the efficiency of alternative vaccines for immune protection is still inadequate. Consequently, there exists an urgent need for safer and more effective innovative vaccines in animal husbandry. In this study, we aimed to develop a lipid nanoparticle mRNA vaccine based on VP1-3A-3D epitopes from serotype O FMD and to verify its specific expression within cytoplasmic and injection sites. Our findings demonstrated that mRNA transfected into primary spleen cells derived from guinea pigs induced cytokine release, promoted differentiation of both CD4 + T and CD8 + T lymphocytes, and enhanced lymphocyte proliferation rates. Following immunization of mRNA vaccine in guinea pigs, we observed increased differentiation of both CD4 + T and CD8 + T cells, alongside elevated levels of cytokine secretion. Additionally, this vaccination induced the production of specific IgG antibodies as well as neutralizing antibodies. Importantly, our vaccine provided complete protection for all six guinea pigs against a lethal challenge of 100 GPID 50 , with histopathological scores indicating protection equivalent to that conferred by the inactivated vaccine. The viral load results demonstrated that the vaccine group significantly reduced viral copy numbers in serum and effectively decreased the concentration of the inflammatory cytokine IL-1β. Furthermore, during the pre-immune phase following vaccination with the mRNA vaccine in pigs, heightened cytokine secretion was observed, along with the inhibition of viral replication. Simultaneously, the neutralizing antibody titer in the serum remained stable over 4 months. Immunofluorescence analysis of spleen tissues from both guinea pigs and pigs demonstrated marked activation and increased expression of CD4 + and CD8 + T lymphocytes, as well as macrophages, in the mRNA vaccine group. In summary, this study suggests that the serotype O FMD mRNA vaccine is a promising candidate for further development in the fight against FMDV.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2025) studied Foot-and-mouth disease (FMD) (n=102). Serotype O FMD mRNA vaccine vs. PBS (blank control) and commercial inactivated vaccine was evaluated on Survival rate against lethal challenge of 100 GPID50 in guinea pigs. The serotype O FMD mRNA vaccine provided complete protection (100% survival) for guinea pigs against a lethal challenge of 100 GPID50, with protection equivalent to the inactivated vaccine.
Synapse has enriched 10 related papers. Consider them for comparative context: